Merck & Co., Inc. and BioImage A/S sign licensing deal on Redistribution® Technology
The Redistribution® patent portfolio covers a broad range of methods aimed at studying intracellular signalling events. The Redistribution® technology enables high throughput screening on a number of drug discovery live cell screening applications, such as protein translocations, receptor internalizations, protein trafficking, secretions, etc. BioImage is presently out licensing the portfolio to a number of leading companies within the life science industry.
"We are delighted and proud to have a world class pharmaceutical company like Merck license our patent portfolio", said Dr. Patrik Dahlén, CEO of BioImage. "By using the Redistribution® technology, researchers can track proteins in living cells and screen for compounds that affect specific cellular signalling pathways. This improves the biological relevance of drug screening and helps increase the speed and accuracy of drug discovery and development. At BioImage, we have developed an extensive experience in the area of protein translocation assays and pathway screening."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.